Irreversible Electroporation for Treatment of Locally Advanced Pancreatic Cancer

video

Contributors: Robert C.G. Martin, II Locally advanced pancreatic cancer (Stage 3) is defined by encasement or abutment of vital venous and arterial structures.  Irreversible electroporation (IRE) represents an effective local non-thermal ablation modality for treatment of solid tumors involving critical vascular and biliary structures.  Electroporation creates pores in the cell membrane and disrupts the ionic gradients while sparing the extracellular matrix, resulting in preservation of blood vessel and biliary scaffolding. DOI: http://dx.doi.org/10.17797/yonbav6fdz Editor Recruited by: Jeffrey B. Matthews

Selection and Optimal Irreversible Electroporation Technique in Pancreatic Adenocarcinoma

webinar

In this session our panelists will discuss:
- Optimal induction-based therapy in Stage 3 pancreatic adenocarcinoma
- Optimal pre-operative planning for patients undergoing IRE technique
- Optimal intra-operative IRE technique in pancreatic adenocarcinoma

---

Director of Division of Surgical Oncology
University of Louisville

Robert C. G. Martin, II, M.D. PhD, is The Sam and Lolita Weakley Endowed Chair in Surgical Oncology, The Director of the Division of Surgical Oncology, faculty member of the James Graham Brown Cancer Center, and a Professor in the Department of Surgery. He was appointed to the University of Louisville in 2002 as an Assistant Professor and achieved Professor of Surgery in 2011. Dr. Martin received his M.D. from the University of Louisville School of Medicine (1995), his surgical oncology training and hepato-pancreatico-biliary training from Memorial Sloan-Kettering Cancer Center (2002), and his PhD from the Department of Pharmacology and Toxiciology (2008) at the University of Louisville School of Medicine. Dr. Martin’s clinical interests are focused on the multi-disciplinary care and surgical management of patients with upper GI malignancies, including esophageal, gastric, duodenal, liver, biliary, and pancreatic cancers.